candoxatrilat has been researched along with bq 123 in 1 studies
| Studies (candoxatrilat) | Trials (candoxatrilat) | Recent Studies (post-2010) (candoxatrilat) | Studies (bq 123) | Trials (bq 123) | Recent Studies (post-2010) (bq 123) |
|---|---|---|---|---|---|
| 46 | 10 | 1 | 1,391 | 63 | 152 |
| Protein | Taxonomy | candoxatrilat (IC50) | bq 123 (IC50) |
|---|---|---|---|
| Endothelin-1 receptor | Homo sapiens (human) | 0.017 | |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | 0.014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferro, CJ; Haynes, WG; Spratt, JC; Webb, DJ | 1 |
1 trial(s) available for candoxatrilat and bq 123
| Article | Year |
|---|---|
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Blood Pressure; Coronary Vessels; Cross-Over Studies; Cyclohexanecarboxylic Acids; Enalapril; Endothelin-1; Humans; Hypertension; Injections, Intra-Arterial; Male; Middle Aged; Myocardium; Neprilysin; Peptides, Cyclic; Protease Inhibitors; Renin; Single-Blind Method; Thiorphan; Vasoconstriction | 1998 |